News

Antibiotics lessen the diversity of microbes in the lungs of cystic fibrosis (CF) patients, and make these people more susceptible to infections with bacteria that are highly resistant to antibiotics, researchers reported. The study “Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity”…

Vertex Pharmaceuticals has entered a partnership with the Danish pharmaceutical organization Amgros to one day make Vertex’s cystic fibrosis (CF) therapies available for Danish patients. The collaboration was made through an access contract, a first-of-its-kind contract that gives Danish CF patients access to all Vertex’s current and future CF…

Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational treatment to prevent hearing loss and balance disorders in patients taking high doses of aminoglycoside antibiotics, including cystic fibrosis (CF) patients. Under the terms of the agreement, Oricula will provide scientific…

AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential treatment for exocrine pancreatic insufficiency (EPI) achieved its goals, namely a statistically significant improvement in fat absorption. EPI, often caused by cystic fibrosis, is a disease resulting from…

Sound Pharmaceuticals (SPI) will present data on the incidence and severity of ototoxicity in cystic fibrosis (CF) patients who received tobramycin for the treatment of acute pulmonary exacerbations. The presentation, which was accepted as a late-breaking abstract, will be given at the upcoming North American Cystic Fibrosis…

Biopharma Vivus recently supported the Dallas and Fort Worth chapters of the Cystic Fibrosis Foundation (CFF) in their CF Climb fundraising event at AT&T Stadium in Arlington, Texas, providing both sponsorship and employee participation. The company’s backing corresponded with its launch of Pancreaze (pancrelipase), approved…

Inhaled nitric oxide, AIT Therapeutics’ therapy candidate, was shown to have significant antibacterial activity against the bacterium Mycobacterium abscessus (M. abscessus), which often infects the airways of patients with cystic fibrosis. AIT announced the results of a laboratory study in a poster presentation titled, “High-dose…

A record 5,000 people from dozens of countries will gather next month in Denver for the 32nd Annual North American Cystic Fibrosis Conference (NACFC) — the world’s largest event focused on cystic fibrosis (CF) research and care. The Oct. 18-20 event at Denver’s Colorado Convention Center features 24 symposium sessions, 31…

Consuming dietary flavonoids — compounds naturally found in fruits, vegetables, chocolate, and beverages like wine and tea — may be associated with changes in gut bacteria that potentially affect the body’s metabolism, immune function, and inflammation in patients with cystic fibrosis (CF), a small…

The U.S. Food and Drug Administration gave positive feedback to the design of AmpliPhi Biosciences’ two proposed clinical trials of its Pseudomonas aeruginosa-targeting treatment candidate AB-PA01, the company announced in a press release. P. aeruginosa is the major cause of lung infections in cystic fibrosis patients.